Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (April 2024)
32 slides from Sonoma Pharmaceuticals's investor presentation, Apr 2, 2024
Slide 1: Sonoma Pharmaceuticals, Inc. Investor Presentation April 2024
Sonoma Pharmaceuticals, Inc. Investor Presentation April 2024
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: About Sonoma
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid ( HOCl ) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non - toxic disinfectants. Sonoma’
Slide 4: Investment Highlights
Over 20 years of experience developing and manufacturing products containing HOCl , over 100 research articles, papers and clinical and case studies, over 50 active U.S. and international patents, and continual product innovation Hypochlorous Acid Industry Leader 21 U.S. FDA clearances as 510(k) med
Slide 5: What is Hypochlorous Acid?
What is Hypochlorous Acid? During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H 2 O 2 ) and the activated granule enzyme myeloperoxidase converts H 2 O 2 to hypochlorous acid (HOCl) 5
Slide 6: Sonoma's Microcyn Technology
Sonoma’s Microcyn ® Technology Patented, Stabilized Triple - Action Topical Technology • HOCl kills microbes including bacteria, fungi and viruses while assisting healing • R elieves pain and itch • Improves wound care by cleaning and moistening the wound and peri - wound area • Safely manage skin a
Slide 7: Sonoma's Microcyn Technology
Sonoma’s Microcyn ® Technology Unparalleled Safety • No drug - to - drug interaction or contraindications • Millions of patients treated worldwide without a single report of serious adverse effect • 30+ human clinical trials with over 1,500 patients • Products contain all - natural hypochlorous acid
Slide 8: Safety in Dermatology Products
Safety in Dermatology Products Recently, there has been concern by dermatologists that popular dermatology products can form benzene , a known carcinogen. • Citizen petition by Valisure , LLC, an independent testing laboratory for pharmaceuticals, requested an FDA recall of certain over - the - coun
Slide 9: Wide Range of Applications
Wide Range of Applications 9 Wound Care Dermatology Eye Care Oral and Dental Care Animal Health Care Surface Disinfectants Podiatry Nasal Care
Slide 10: Research articles and case and clinical studies
Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology • Dermodacyn ® Disinfecting solution study on viability of SARS - CoV - 2, see https://www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn ® study on cellul
Slide 11: Cutting Edge Manufacturing
• 57,153 square foot state - of - the - art facility • ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals • Shipping to over 55 countries • Highly trained staff of 162 employees CUTTING EDGE MANUFACTURING Flexible operat
Slide 12: Located in Guadalajara, Mexico
Located in Guadalajara, Mexico Laboratory Packaging Area Labeling Boxing Ready for shipment Warehouse Air Systems Product Water Treatment System Materials Testing Laboratory Manufacturing Facility 12
Slide 13: Robust International Distribution Network
Robust International Distribution Network OVER 40 GLOBAL PARTNERS generating strong revenues internationally and in the U.S. • Expand presence in new markets by replicating what works in existing markets • Continue to add new distribution partners and grow existing relationships • Continue co - deve
Slide 14: Growth Strategy
Continue to introduce new high margin products Manufacturing capabilities can support significant future growth, leading to improved margins overall • Launch new applications of Sonoma’s Microcyn ® technology for consumer - focused products, including in the dermatology and aesthetic space Growth St
Slide 15: New Market Opportunities
Sonoma is expanding its partnerships and product offerings in the all - natural skin care and medical spa industries. • The global natural skin care products market size was valued at $6.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030. 1
Slide 16: Recent Business Developments: new products
Introduction of new products using our Microcyn ® technology • On January 23 , 2024 , Sonoma launched Lumacyn TM Clarifying Mist , a new direct - to - consumer skincare product, in the United States . Lumacyn is an all - natural daily toner formulated with Microcyn ® technology to soothe the skin an
Slide 17: Recent Business Developments
Expanding commercialization opportunities by investing in R&D • In March 2023 , Sonoma announced new EPA claims for its Nanocyn ® Hospital - Grade Disinfectant f or effective use against MRSA , Salmonella , Norovirus , Poliovirus , and as a fungicide . Nanocyn was previously approved for use against
Slide 18: Continuously expanding our distributor network
Continuously expanding our distributor network • Entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. , one of the largest pharmaceutical companies in South Korea, in January 2023 for the marketing and distribution of Primocyn TM Skin Solution products • Sonoma’s Microcyn ® R
Slide 19: Management
Management Amy Trombly CEO Amy Trombly is our Chief Executive Officer and also serves on our Board of Directors . She counseled public companies for over two decades in corporate and securities law and mergers and acquisitions, including as the owner and manager of Trombly Business Law, PC . In her
Slide 20: Key Financial Metrics
Key Financial Metrics * dollars in thousands Year Ended Year Ended Nine Months Ended Nine Months Ended March 31, 2022* March 31, 2023 * December 31, 2022 * (unaudited) December 31, 2023 * (unaudited) $12,628 $13,272 $10,258 $9,296 Total Revenues $3,993 $4,477 $3,613 $3,654 Gross Profit $9,880 $9,047
Slide 21: Revenue Metrics
Revenue Metrics Revenues by revenue source: Year Ended March 31, Nine Months Ended December 31, 2022 2023 2022 2023 $ 9,010 $ 9,426 $ 7,050 $ 7,286 Human Care 3,169 2,500 1,957 1,688 Animal Care 449 1,346 1,251 322 Service and Royalty $ 12,628 $ 13,272 $ 10,258 $ 9,296 Revenues by geographic region:
Slide 22: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court , Suite 150 Boulder , CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Slide 23: Appendix: Product Portfolio
APPENDIX: Product Portfolio
Slide 24: Diverse Product Portfolio
Diverse Product Portfolio United States Podiacyn Everyday Foot Care Microcyn Rx Skin & Wound Care Regenacyn Scar Gel Epicyn Antimicrobial Facial Cleanser Nanocyn Hospital Grade Disinfectant Levicyn Antimicrobial Dermal Spray Celacyn Scar Management Gel Rejuvacyn Skin Repair Reliefacyn Itch, Burn, Ra
Slide 25: Lumacyn Clarifying Mist
Lumacyn TM Clarifying Mist introduced January 2024 • New high - end direct to consumer skincare product for daily management of skin irritations
Slide 26: U.S. office dispense products
U.S. office dispense products exclusively for skin care professionals • Generates highest margins for Sonoma • Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin 26
Slide 27: U.S. Animal Health Care
U.S. Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail cha
Slide 28: EU Products
Epicyn ® Dermatology Gramaderm ® Dermatology Pediacyn ® Dermatology Mucoclyns ® Decontamination solution Microdacyn60 ® Oral Care Blocked nose or sinuses Sinudox ® Nasal care Blepharitis treatment Ocudox ® Eye lid solution Exposure to germs and pathogens Mouth and throat infections Keloid or hypertr
Slide 29: Direct-to-consumer products
Direct - to - consumer products available through Shopify, Amazon and Amazon EU U.S. Products EU Products 29
Slide 30: Middle East
Middle East Microdacyn Microsafe uw Se ¢ Microsafe | Disinfectant & Sanitizer a | <l 1)
Slide 31: Latin America, Australia and New Zealand
Gramacyn Kit for Acne Skin Latin America Epicyn Treat Scars Right from the Start Australia and New Zealand 31
Slide 32: Asia
Singapore, Malaysia, Thailand, Indonesia Wound Care South Korea BioDerm Biodacyn60 Wound Care Hong K ong Microdacyn60 Oral Care China Microcyn The Philippines M icrodacyn MicrocynAH Asia 32
Sonoma Pharmaceuticals — Investor Presentation (April 2024) on 6ix